Vidya Maiya
About
In The Last Decade
Vidya Maiya
13 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 68
- Oncology 1.4k
- Cancer Research 531
- Pulmonary and Respiratory Medicine 484
- Immunology 433
- Molecular Biology 255
Countries citing papers authored by Vidya Maiya
This map shows the geographic impact of Vidya Maiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vidya Maiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vidya Maiya more than expected).
Fields of papers citing papers by Vidya Maiya
This network shows the impact of papers produced by Vidya Maiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vidya Maiya. The network helps show where Vidya Maiya may publish in the future.
Co-authorship network of co-authors of Vidya Maiya
This figure shows the co-authorship network connecting the top 25 collaborators of Vidya Maiya. A scholar is included among the top collaborators of Vidya Maiya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vidya Maiya. Vidya Maiya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 6 | |
| 3 | 10 | |
| 4 | 1 | |
| 5 | 5 | |
| 6 | 50 | |
| 7 | 15 | |
| 8 | 14 | |
| 9 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial breakdown → | 718 |
| 10 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial breakdown → | 846 |
| 11 | 1 | |
| 12 | 32 | |
| 13 | Cyclosporine experience in nephrotic syndrome. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.